Research Information System
TURKISH JOURNAL OF BIOCHEMISTRY-TURK BIYOKIMYA DERGISI, vol.50, no.6, pp.870-877, 2025 (SCI-Expanded, Scopus, TRDizin)
Objectives Wilson's Disease (WD) leads to copper accumulation in the liver and brain. It generates oxidative stress, which can damage the liver and central nervous system (CNS). The concentrations of oxidized lipid products, such as prostaglandins and isoprostanes, in blood and urine can indicate both the presence and the extent of damage. However, there is limited research specifically investigating these oxidative stress biomarkers in WD, making this study a novel contribution to the field.Methods In this study, serum and 24-h urine samples were collected from a total of 64 individuals, including 22 WD patients with hepatic involvement (HI-WD), 17 with neurological-hepatic involvement (NHI-WD), and 25 healthy controls (HC). A Liquid Chromatography Mass Spectrometry (LC-MS/MS) method was developed and validated to quantify specific prostaglandins and isoprostanes in serum and urine samples.Results The results showed significant differences in the levels of iPF2 alpha-III, 2,3-dinor-iPF2 alpha-III, 5-iPF2 alpha-VI in serum as well as PGE2, PGD2, PGF2 alpha, iPF2 alpha-III and 5-iPF2 alpha-VI in 24-h urine samples between WD and HC groups. Notably, the concentration of PGD2 in urine was significantly higher in the NHI-WD group compared to both the HC and HI-WD groups. Our novel urine biomarker panel has the potential to be used for grading disease severity, monitoring therapy and assessing CNS involvement in WD.Conclusions It represents one of the first to explore a panel of oxidative stress biomarkers, particularly prostaglandins and isoprostanes, in both serum and urine samples in WD patients, making it an original contribution to the current literature on WD.